While in contrast to our in vitro findings, these results support previous data from our laboratory which showed that further targeting the AR in ENZ resistant MR49F tumors in vivo provides only short-lived benefit in terms of slowing tumor growth [8] as well as data from clinical trials showing that monotherapy with Lapatinib is not effective in PCa patients [21, 33]. The gene discussed is AR; the disease is neoplasm.